Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)

Autor: Dimopoulos, M.A. Cavo, M. Mateos, M.-V. Facon, T. Heeg, B. van Beekhuizen, S. Gebregergish, S.B. Nair, S. Pisini, M. Lam, A. Slavcev, M.

D-VMP is a novel treatment for transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). D-VMP significantly prolonged PFS versus VMP in the ALCYONE trial. The FIRST trial investigated Rd given in 28-day cycles until disease progression, Rd

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::487cd0e5f97d4587efcd472a6c0422a4
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078649

Zobrazit plný text záznamu

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis

Autor: Hungria, V. Martínez-Baños, D.M. Mateos, M.-V. Dimopoulos, M.A. Cavo, M. Heeg, B. Garcia, A. Lam, A. Machnicki, G. He, J. Fernandez, M.

Introduction: The phase 3 ALCYONE study demonstrated significantly longer progression-free and overall survival (PFS/OS) and higher overall response rates (ORR) with daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus VMP alone in t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::51607f5b1e7a1b7ca4d5f3823e4c00b6
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103504

Zobrazit plný text záznamu

The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison

Autor: Mateos, M.-V. San-Miguel, J. Goldschmidt, H. Sonneveld, P. Dimopoulos, M.A. Heeg, B. Hashim, M. Deraedt, W. Hu, P. Lam, A. He, J.

For patients with newly diagnosed multiple myeloma (NDMM) who are transplant ineligible, bortezomib-melphalan-prednisone (VMP) demonstrated superior efficacy based on the VISTA trial. In subsequent trials, twice-weekly bortezomib was limited to the f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::e3adfc4a15c11276a2ca311380f0bdf8
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078530

Zobrazit plný text záznamu

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Autor: Munshi, N.C. Avet-Loiseau, H. Anderson, K.C. Neri, P. Paiva, B. Samur, M. Dimopoulos, M. Kulakova, M. Lam, A. Hashim, M. He, J. Heeg, B. Ukropec, J. Vermeulen, J. Cote, S. Bahlis, N.

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS) and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma (MM) using a systematic literature review and meta-analysis. Medlin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::209e67fc80077107c86ffffbb233d7f2
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103379

Zobrazit plný text záznamu